E-mail: akishita-tky@umin.ac.jp Received 17 November 2009; revised 6 January 2010; accepted 3 February 2010; published online 26 March 2010 Testosterone and metabolic syndrome M Akishita et al 588 on insulin injection or hypoglycemic agent drugs or with hemoglobin A1c 48%, and subjects on ...
One potential explanation for these apparently conflicting observations is that the CV risk/benefit ratio may vary by the route of TRT administration. Testosterone can be administered by intramuscular injection of long-acting T esters, transdermally by patch or gel and orally as testosterone undecanoate...